Program Status
Active, not recruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
YesDrugs
NGM831, NGM831 plus pembrolizumabTags
MSI-H/ MMRd, MSS/ MMRpComments
NGM831 (a ILT3 antagonist) as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors (CRC included). Trial starts with NGM831 monotherapy, in dose scalation.
Helpful Links
anti-LILRB4 monoclonal antibody NGM831| Location | Location Status |
|---|---|
| United States | |
|
NGM Clinical Study Site Gilbert, Arizona 85234 |
Active, not recruiting |
|
NGM Clinical Study Site Los Angeles, California 90025 |
Active, not recruiting |
|
NGM Clinical Study Site Sarasota, Florida 34232 |
Active, not recruiting |
|
NGM Clinical Study Site Tampa, Florida 33612 |
Active, not recruiting |
|
NGM Clinical Study Site Grand Rapids, Michigan 49546 |
Active, not recruiting |
|
NGM Clinical Study Site New York, New York 10016 |
Active, not recruiting |
|
NGM Clinical Study Site Oklahoma City, Oklahoma 73104 |
Active, not recruiting |
|
NGM Clinical Study Site Austin, Texas 78758 |
Active, not recruiting |
|
NGM Clinical Study Site Houston, Texas 77030 |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
* Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
* Adequate bone marrow, kidney and liver function
* Performance status of 0 or 1.
* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion Criteria
Exclusion Criteria:
* Prior treatment targeting ILT3.
* Prior treatment targeting LAIR1.
